In this randomized phase II trial (NCT00524277), breast cancer patients (any Her2 and ER expression) with no evidence of disease after completing standard treatments, including trastuzumab (Herceptin), either received the Her2-derived HLA class I peptide, called GP2, in combination with GM-CSF, or GM-CSF alone [83]. This evidence concerns the gene CSF2 and breast cancer.